JP2021522248A5 - - Google Patents

Info

Publication number
JP2021522248A5
JP2021522248A5 JP2020559465A JP2020559465A JP2021522248A5 JP 2021522248 A5 JP2021522248 A5 JP 2021522248A5 JP 2020559465 A JP2020559465 A JP 2020559465A JP 2020559465 A JP2020559465 A JP 2020559465A JP 2021522248 A5 JP2021522248 A5 JP 2021522248A5
Authority
JP
Japan
Prior art keywords
composition
cationic
nucleic acid
additive
nano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559465A
Other languages
English (en)
Japanese (ja)
Other versions
JP7256824B2 (ja
JP2021522248A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/060646 external-priority patent/WO2019207061A1/en
Publication of JP2021522248A publication Critical patent/JP2021522248A/ja
Publication of JP2021522248A5 publication Critical patent/JP2021522248A5/ja
Application granted granted Critical
Publication of JP7256824B2 publication Critical patent/JP7256824B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559465A 2018-04-25 2019-04-25 粒子状製剤用の凍結保護剤 Active JP7256824B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18169325 2018-04-25
EP18169325.0 2018-04-25
EP18189010.4 2018-08-14
EP18189010 2018-08-14
PCT/EP2019/060646 WO2019207061A1 (en) 2018-04-25 2019-04-25 Cryoprotective agents for particulate formulations

Publications (3)

Publication Number Publication Date
JP2021522248A JP2021522248A (ja) 2021-08-30
JP2021522248A5 true JP2021522248A5 (cg-RX-API-DMAC7.html) 2022-04-28
JP7256824B2 JP7256824B2 (ja) 2023-04-12

Family

ID=66240151

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559465A Active JP7256824B2 (ja) 2018-04-25 2019-04-25 粒子状製剤用の凍結保護剤
JP2020558887A Pending JP2021522228A (ja) 2018-04-25 2019-04-25 Rnaの送達用の脂質に基づく製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020558887A Pending JP2021522228A (ja) 2018-04-25 2019-04-25 Rnaの送達用の脂質に基づく製剤

Country Status (13)

Country Link
US (2) US20210137840A1 (cg-RX-API-DMAC7.html)
EP (3) EP4311541A3 (cg-RX-API-DMAC7.html)
JP (2) JP7256824B2 (cg-RX-API-DMAC7.html)
KR (2) KR20210021943A (cg-RX-API-DMAC7.html)
CN (2) CN112153985B (cg-RX-API-DMAC7.html)
AU (2) AU2019258678B2 (cg-RX-API-DMAC7.html)
BR (2) BR112020021037A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098259C (cg-RX-API-DMAC7.html)
ES (2) ES2960939T3 (cg-RX-API-DMAC7.html)
MX (2) MX2020011167A (cg-RX-API-DMAC7.html)
PL (1) PL3784285T3 (cg-RX-API-DMAC7.html)
WO (2) WO2019207060A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202006025B (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
BR112014024131A2 (pt) 2012-03-29 2017-07-25 Shire Human Genetic Therapies lipídios catiônicos ionizáveis
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
EA201591283A1 (ru) 2013-03-14 2016-02-29 Шир Хьюман Дженетик Терапис, Инк. Количественная оценка эффективности кэп матричной рнк
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
US10266559B2 (en) 2013-03-14 2019-04-23 Translate Bio, Inc. Ribonucleic acids with 4′-thio-modified nucleotides and related methods
MX2015011945A (es) 2013-03-14 2015-12-01 Shire Human Genetic Therapies Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
AU2014340149B2 (en) 2013-10-22 2020-12-24 Shire Human Genetic Therapies, Inc. CNS delivery of mRNA and uses thereof
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
AU2015357562B2 (en) 2014-12-05 2021-10-21 Translate Bio, Inc. Messenger RNA therapy for treatment of articular disease
AU2017283479B2 (en) 2016-06-13 2023-08-17 Translate Bio, Inc. Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
CN116549671A (zh) 2016-11-10 2023-08-08 川斯勒佰尔公司 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
ES2899323T3 (es) 2017-02-27 2022-03-10 Translate Bio Inc Métodos de purificación de ARN mensajero
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US11530298B2 (en) 2017-06-12 2022-12-20 Translate Bio, Inc. Poly(phosphoesters) for delivery of nucleic acids
US10780183B2 (en) 2017-06-19 2020-09-22 Translate Bio, Inc. Messenger RNA therapy for the treatment of Friedreich's ataxia
MA51306A (fr) 2017-12-20 2020-10-28 Translate Bio Inc Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
JP7256824B2 (ja) 2018-04-25 2023-04-12 エスリス ゲーエムベーハー 粒子状製剤用の凍結保護剤
AU2019271215B2 (en) 2018-05-16 2024-09-12 Translate Bio, Inc. Ribose cationic lipids
US12076439B2 (en) 2018-05-24 2024-09-03 Translate Bio, Inc. Thioester cationic lipids
EP3802507A1 (en) 2018-05-30 2021-04-14 Translate Bio, Inc. Vitamin cationic lipids
CN118436618A (zh) 2018-05-30 2024-08-06 川斯勒佰尔公司 信使rna疫苗及其用途
MA52762A (fr) 2018-05-30 2021-04-14 Translate Bio Inc Lipides cationiques comprenant une fraction stéroïdienne
WO2020023533A1 (en) 2018-07-23 2020-01-30 Translate Bio, Inc. Dry power formulations for messenger rna
CA3109548A1 (en) * 2018-08-14 2020-02-20 Ethris Gmbh Lipid-based formulations containing salts for the delivery of rna
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
EP3849617A1 (en) 2018-09-14 2021-07-21 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
CA3115119A1 (en) 2018-11-08 2020-05-14 Translate Bio, Inc. Methods and compositions for messenger rna purification
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
US12257305B2 (en) 2018-11-21 2025-03-25 Translate Bio, Inc. Cationic lipid compounds
WO2020146344A1 (en) 2019-01-07 2020-07-16 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
WO2020214946A1 (en) 2019-04-18 2020-10-22 Translate Bio, Inc. Cystine cationic lipids
US11453877B2 (en) 2019-05-15 2022-09-27 Translate Bio, Inc. Methods for purification of messenger RNA
EP3986858A1 (en) 2019-06-21 2022-04-27 Translate Bio, Inc. Tricine and citric acid lipids
AU2020315962B2 (en) 2019-07-23 2026-02-12 Translate Bio, Inc. Stable compositions of mRNA-loaded lipid nanoparticles and processes of making
CA3155003A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
EP4529928A3 (en) 2019-10-09 2025-05-28 Translate Bio, Inc. Compositions, methods and uses of messenger rna
BR112022006534A2 (pt) 2019-10-24 2022-07-05 Novago Therapeutics Ag Anticorpos anti-nogo-a
JP2023508881A (ja) 2019-12-20 2023-03-06 トランスレイト バイオ, インコーポレイテッド Mrna担持脂質ナノ粒子を調製する改善されたプロセス
CN115427021A (zh) 2020-02-25 2022-12-02 翻译生物公司 制备负载mrna的脂质纳米颗粒的改进方法
WO2021226468A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Improved compositions for cftr mrna therapy
ES3066134T3 (en) 2020-05-14 2026-05-11 Translate Bio Inc Peg lipidoid compounds
WO2021245184A1 (en) 2020-06-02 2021-12-09 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
WO2025056938A1 (en) * 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
US12678406B2 (en) 2020-10-12 2026-07-14 Translate Bio Inc. Process of preparing ice-based lipid nanoparticles
CN116438298A (zh) 2020-10-15 2023-07-14 翻译生物公司 信使rna的大规模合成
US12576030B2 (en) 2020-11-09 2026-03-17 Translate Bio, Inc. Compositions for delivery of codon-optimized mRNA
WO2023009422A1 (en) * 2021-07-26 2023-02-02 Modernatx, Inc. Processes for preparing lipid nanoparticle compositions for the delivery of payload molecules to airway epithelium
CN121844046A (zh) * 2023-09-11 2026-04-10 C·米库尔卡 用于递送肠促胰岛素剂的rna组合物
WO2026006617A1 (en) * 2024-06-27 2026-01-02 Genentech, Inc. Lyophilized and frozen mrna-lnp formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
JPS607932A (ja) * 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソーム懸濁液およびその製法
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
WO1999000113A1 (en) 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Dna/脂質複合体の単一バイアル製剤
US6017700A (en) 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
TW520294B (en) * 1998-01-08 2003-02-11 Res Dev Foundation Stabilization of lipid: DNA formulations during nebulization
WO2005121369A2 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
CN1981044B (zh) * 2004-06-07 2010-05-05 普洛体维生物治疗公司 包封干扰rna的脂质
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
US9393215B2 (en) * 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
KR101388320B1 (ko) 2005-12-15 2014-04-22 뽈리쁠뤼스-트랑스펙씨옹 양이온성 올리고뉴클레오티드, 이를 제조하기 위한 자동화방법 및 이의 용도
CN101686939B (zh) 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
CN104382853A (zh) * 2008-10-16 2015-03-04 玛瑞纳生物技术有限公司 基因沉默治疗剂的脂质体有效递送方法和组合物
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
EA022786B1 (ru) 2009-07-31 2016-03-31 Этрис Гмбх Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
AU2012255194B2 (en) * 2011-05-16 2017-01-05 Danmarks Tekniske Universitet Charge triggering of self-organized nanoparticles
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
GB201118704D0 (en) 2011-10-28 2011-12-14 Univ Oxford Cystic fibrosis treatment
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
EA037448B1 (ru) 2012-06-08 2021-03-30 Этрис Гмбх Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция
ES2967701T3 (es) * 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
KR102285326B1 (ko) 2013-06-28 2021-08-04 에트리스 게엠베하 Rna를 세포에 도입하기 위한 조성물
CN110003066B (zh) * 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
JP2017507946A (ja) * 2014-02-26 2017-03-23 エスリス ゲーエムベーハーethris GmbH Rnaを胃腸内投与するための組成物
DK3221293T3 (da) 2014-11-18 2023-04-03 Arcturus Therapeutics Inc Ioniserbar kationisk lipid til RNA-afgivelse
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
EP3247328B1 (en) 2015-01-21 2026-01-07 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
WO2016118724A1 (en) * 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2018010815A1 (en) * 2016-07-15 2018-01-18 Biontech Rna Pharmaceuticals Gmbh Formulation for administration of rna
EP3538067A1 (en) * 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US20180153822A1 (en) 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
JP7256824B2 (ja) 2018-04-25 2023-04-12 エスリス ゲーエムベーハー 粒子状製剤用の凍結保護剤
CA3109548A1 (en) 2018-08-14 2020-02-20 Ethris Gmbh Lipid-based formulations containing salts for the delivery of rna

Similar Documents

Publication Publication Date Title
ES2314408T3 (es) Formulaciones de hfc en solucion que contienen un anticolinergico.
Myrdal et al. Advances in metered dose inhaler technology: formulation development
JP3056784B2 (ja) エアゾール医薬製剤
JP3026841B2 (ja) 医 薬
JP3210012B2 (ja) 医薬品
JP3280974B2 (ja) 医 薬
JP2021522228A5 (cg-RX-API-DMAC7.html)
JP3026840B2 (ja) 医 薬
JP2915574B2 (ja) 医療用エアロゾル製剤
TW528606B (en) Pharmaceutical formulations for aerosols with two or more active substances
JP2016512494A5 (cg-RX-API-DMAC7.html)
JPH10510521A (ja) エアゾール処方物用噴射剤混合物
JPH06501710A (ja) ベクロメタゾン17,21ジプロピオネートを含んで成るエアロゾル製剤
JP2003521459A (ja) 医薬用エーロゾル製剤
JPH07503476A (ja) 医薬
JP2002541183A (ja) 医薬用エアゾール製剤
JP2024507394A5 (cg-RX-API-DMAC7.html)
JP2016534142A5 (cg-RX-API-DMAC7.html)
JP2019524648A (ja) ニコチン粒子および組成物
JP2014224147A5 (cg-RX-API-DMAC7.html)
JP2001525354A (ja) 薬用エアロゾル組成物
CN102905694B (zh) 吸入溶液
CN102238939B (zh) 药物气溶胶组合物
BR102012026195B1 (pt) método de preparação de uma formulação de nicotina adequada para inalação e método para a realização de uma terapia de substituição ou retirada de tabaco
TWI924704B (zh) 茚達特羅(indacaterol)之液體調配物